Article Text
Statistics from Altmetric.com
Description
A 3-month-old girl presented with 5 days of abnormal eye movements. Neurological examination was significant for axial hypotonia. MRI of the brain revealed extensive T2 prolongation and enhancement within the optic chiasm, optic nerves, bilateral basal ganglia, cerebellum and temporal lobes (figure 1). MRI of the spine showed extensive enhancement along the cervicomedullary junction and cervical and thoracic cord consistent with leptomeningeal metastatic disease (figure 2). The patient underwent right frontotemporal craniotomy for debulking of the tumour and biopsy. Neuropathology revealed a moderately cellular tumour with uniform nuclei, small amounts of myxoid material and perivascular clearing consistent with pilomyxoid astrocytoma (PMA) (figure 3). Molecular analysis demonstrated a novel MUTYH Y165C mutation. The patient died 17 months after diagnosis despite multimodal chemotherapy regimens due to disease progression.
PMA is distinct from pilocytic astrocytoma (PA). PMA demonstrates monomorphous piloid cells in a loose fibrillar and myxoid background, preferentially involves the hypothalamus, and the mean age at diagnosis is 18 months. PMA is more aggressive than PA, with higher rates of cerebrospinal fluid dissemination and shorter progression-free and overall survival. There is currently no specific treatment for PMA.1
MUTYH is a DNA glycosylase important in base excision repair and thus has tumour-suppressing properties.2 MUTYH mutations are traditionally implicated in familial colorectal cancer syndromes and also double the incidence of extraintestinal malignancies, specifically ovarian, bladder and skin cancer.2 Recent case reports have described MUTYH mutations in paediatric high-grade gliomas.3 Our findings highlight the first reported case of MUTYH mutation in PMA.
Learning points
MUTYH mutations are classically implicated in familial colorectal cancer syndromes and increase the risk of ovarian, bladder and skin cancer but have not yet been shown to increase the risk of primary central nervous system tumours.
A growing body of the literature suggests that MUTYH may function as a broad tumour suppressor and has been mutated in paediatric high-grade gliomas.
The molecular genetics of PMA are currently poorly characterised; further studies are necessary to understand the role of MUTYH mutations in the pathogenesis of PMA and other CNS neoplasms.
Footnotes
Twitter Follow Yasmin Aghajan at @yaghajan
Contributors YA, MLL, RON and JRC were all involved in analysis and interpretation of this case. All authors have made substantial contributions and were involved in drafting and revising this work. All authors have reviewed the case report and agree to its content prior to submission.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.